Lastest “mesothelioma Center” News

Somaxon awarded 5,000 grant for Silenor under QTDP program
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that it has been awarded a non-taxable grant of approximately $ 245,000 related …
Read more on News-Medical-Net

Comments are closed.